Rate of growth of Merkel cell carcinoma: a unique photographic evidence
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin tumor, mainly linked to Merkel cell polyomavirus (MCPyV) and less often to ultraviolet exposure. Additional risk factors include advanced age and immunosuppression. Although MCC is known to grow rapidly, its exact growth rate has not yet been described. We report a case of a 73-year-old man who developed de novo MCC on the lower eyelid while undergoing immunotherapy with nivolumab. Clinical photographs document the absence of disease in March 2024 and the appearance of a 7 mm papule in October 2024. Histology confirmed the diagnosis. This case represents rare visual evidence of MCC’s rapid progression, suggesting an estimated growth rate of approximately 1 mm/month. A controversial aspect is that MCC developed despite ongoing treatment with a programmed death (PD)-1 checkpoint inhibitor, currently recommended for this cancer. Although anecdotal, this case highlights MCC’s progression and the need for further research and new therapies.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
